ArticleClinical case reports2025
Toxic Epidermal Necrolysis and Recurrent Implantation Failure: Unveiling a Rare Phenomenon During Pregnancy.
Article in Clinical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Toxic Epidermal Necrolysis and Recurrent Implantation Failure: Unveiling a Rare Phenomenon During Pregnancy.Clinical case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hydroxychloroquine (HCQ) is a common treatment for recurrent implantation failure (RIF), which may be associated with diverse side effects. We report a case of a 36-year-old RIF3 pregnant female through in vitro fertilization (IVF) presented to the emergency department with painful, itchy, macular, erythematous, blanchable, and exfoliative skin lesions distributed on the face, upper trunk, and upper limbs. She had been prescribed HCQ about 10 days before embryo transfer for her RIF history. With suspicion of Stevens-Johnson syndrome/Toxic epidermal necrolysis (TEN), HCQ was discontinued, and intravenous immunoglobulins (IVIg), triamcinolone, chlorpheniramine, and body lotion were administered. Considering more than 30% of the total body surface area involvement, within 3 days of treatment, and with favorable improvements, the diagnosis of TEN was confirmed. With the rising popularity of HCQ in immune-related conditions, it is essential to highlight the significance of continuous monitoring for uncommon adverse reactions. The need for vigilance becomes particularly critical in patients requiring immediate intervention to prevent irreversible consequences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.